Skip to main content

Cutaneous & COVID Videos

In this video preview, Drs Larry Green and Esther Freeman discuss the latest data regarding the use of immunomodulators during the COVID-19 pandemic.
In this video, Giovanni Damiani, MD, discusses what additional research is needed to further the understanding of stopping or starting biologics during the COVID-19 pandemic.
A recent study, presented at EADV Virtual, highlighted the risk of severe COVID-19 outcomes among patients with psoriasis treated with biologics. Study author Giovanni Damiani, MD, reviewed the key takeaways of this poster in this video.
Giovanni Damiani, MD, discusses one of the notable findings from his EADV Virtual poster on COVID-19 and biologic use, which was the potential protective effect of IL-17 inhibitors.
In this video, Giovanni Damiani, MD, discusses the results of the poster study he presented at EADV Virtual, which showed patients with psoriasis treated with biologics were less likely to experience worse COVID-19 disease outcomes.
Dr John Koo, member of the medical board of the NPF, explains the common misunderstandings his patients with psoriasis have regarding their disease and therapy in relation to their risk of infection and severe outcomes during the COVID-19 pandemic.
Dr Koo, member of the NPF medical board, outlines what the literature has said about mental health and COVID-19 and how this translates into the disease flares and severity in patients with psoriasis.
In part two of our Coping During COVID series on psoriasis, Dr Gelfand highlights the probability of SARS-CoV-2 transmission for patients with psoriasis as well as dermatologists in their practice.
In this Coping During COVID video, Joel M. Gelfand, MD, MSCE, senior advisor of the Interdisciplinary Autoimmune Summit and member of the National Psoriasis Foundation (NPF) COVID-19 Task Force, discusses how to approach treatment with biologics in patients with psoriasis, citing the current literature, recommendations from the NPF and American Academy of Dermatology, and his own recent clinical experience
Andrew Weinstein, MD, MPH, FAAD, details the measures his practice is taking to prevent the transmission of SARS-CoV-2 and protect staff and patients.
Back to Top